Skip to main content
Mereo BioPharma Group plc logo

Mereo BioPharma Group plc — Investor Relations & Filings

Ticker · MREO ISIN · GB00BZ4G2K23 LEI · 213800U8JQHIJOS5AS09 US Manufacturing
Open in API
Filings indexed 635 across all filing types
Latest filing 2022-05-17 Regulatory Filings
Country GB United Kingdom
Listing US MREO

About Mereo BioPharma Group plc

https://www.mereobiopharma.com/

Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with limited or no treatment options. The company's strategy involves acquiring and advancing promising clinical-stage product candidates that have been de-prioritized by larger pharmaceutical or biotechnology companies. This capital-efficient model allows it to develop a specialized pipeline. Its two lead programs are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Mereo BioPharma also engages in strategic partnerships and out-licenses other clinical assets to deliver impactful treatments to patients.

Recent filings

Filing Released Lang Actions
8-A12B/A
Regulatory Filings Classification · 100% confidence The document is a Form 8-A/A Amendment No. 2 filed with the SEC for registration of securities pursuant to Section 12(b) of the Securities Exchange Act of 1934. It relates to the registration of American Depositary Shares and Ordinary Shares on Nasdaq. The document includes references to prior filings and descriptions of securities but does not contain financial statements or performance data. It is a regulatory filing related to securities registration, not a financial report, earnings release, or management discussion. The document length is 4335 characters, which is relatively short and consistent with a regulatory filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-05-17 English
6-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Mereo BioPharma Group plc, reporting the results of its 2022 Annual General Meeting (AGM) held on May 16, 2022. The content includes detailed voting results on various resolutions such as adoption of the annual report and accounts for the year ended December 31, 2021, re-appointment of auditors, director re-appointments, and approval of new articles of association. The document primarily reports the submission of matters to a vote of security holders and the official voting results. It does not contain the full annual report or financial statements but references them as having been made available previously. The focus on voting results and shareholder resolutions aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (8854 characters) and detailed vote counts further support this classification rather than a brief announcement or a full report. Therefore, the appropriate classification is DVA with high confidence.
2022-05-17 English
6-K
Board/Management Information Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Mereo BioPharma Group plc, with the SEC. The content announces the appointment of a new board member and a change in the chair of the board. It focuses on management changes and provides biographical details of the new appointee and the new chair. There is no financial data, earnings information, or report publication. The primary subject is changes in the company's board of directors. Therefore, the document fits the category of Board/Management Information (MANG). The document length is about 5,055 characters, which is sufficient for a detailed announcement but not a full report. Hence, the classification is MANG with high confidence.
2022-05-17 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Mereo BioPharma Group plc, with the SEC. It provides first quarter 2022 financial information including cash balances, net cash burn, and funding outlook. The document is a periodic report for a quarter but is not a full comprehensive interim or quarterly report with detailed financial statements or analysis. It is a regulatory filing to update investors on financial status and outlook. The length is about 4805 characters, which is relatively short and consistent with a Form 6-K report. There is no indication that this is a full interim report (IR) or annual report (10-K). It is not an earnings release (ER) as it contains more narrative and forward-looking statements. It is not a report publication announcement (RPA) because it contains substantive financial information. Therefore, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings like Form 6-K that do not fit other categories.
2022-05-09 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Mereo BioPharma Group plc. It reports positive top-line efficacy and safety data from a Phase 2 clinical trial (ASTRAEUS) of a drug candidate, alvelestat, including detailed clinical trial design, enrollment, efficacy, safety results, and future plans. The document also includes financial updates such as cash balance and guidance. Form 6-K filings are typically used by foreign private issuers to report material information that is not required in annual or quarterly reports. This document is not an annual report (10-K), interim report (IR), earnings release (ER), or any other specific report type but rather a regulatory filing reporting clinical trial results and company updates. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (15,000 characters) and detailed content confirm it is a substantive filing, not a brief announcement or certification.
2022-05-09 English
20-F
Annual Report FY 2021
2022-03-31 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.